Dyne Therapeutics (NASDAQ:DYN) Posts Earnings Results, Beats Expectations By $0.01 EPS

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.01, RTT News reports. During the same period last year, the business earned ($1.05) earnings per share.

Dyne Therapeutics Trading Up 3.4%

Shares of NASDAQ DYN traded up $0.61 during trading on Monday, reaching $18.22. The stock had a trading volume of 336,444 shares, compared to its average volume of 2,062,577. Dyne Therapeutics has a fifty-two week low of $8.06 and a fifty-two week high of $25.00. The company has a debt-to-equity ratio of 0.15, a quick ratio of 22.25 and a current ratio of 22.25. The business’s 50-day moving average price is $18.05 and its 200-day moving average price is $18.59. The company has a market cap of $3.01 billion, a P/E ratio of -5.15 and a beta of 1.08.

Get Dyne Therapeutics alerts:

Insider Transactions at Dyne Therapeutics

In related news, Director Jason P. Rhodes sold 287,956 shares of Dyne Therapeutics stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $19.68, for a total value of $5,666,974.08. Following the completion of the transaction, the director directly owned 11,663 shares in the company, valued at approximately $229,527.84. This trade represents a 96.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,552,911 shares of company stock valued at $29,694,469 in the last ninety days. Company insiders own 20.77% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

Several hedge funds have recently added to or reduced their stakes in DYN. Aster Capital Management DIFC Ltd acquired a new stake in Dyne Therapeutics during the 4th quarter worth $84,000. Steward Partners Investment Advisory LLC increased its stake in Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after purchasing an additional 2,465 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of Dyne Therapeutics by 275.1% in the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after buying an additional 7,697 shares during the last quarter. Prudential Financial Inc. acquired a new stake in shares of Dyne Therapeutics during the second quarter worth about $111,000. Finally, Creative Planning grew its holdings in shares of Dyne Therapeutics by 23.8% during the second quarter. Creative Planning now owns 14,541 shares of the company’s stock worth $138,000 after buying an additional 2,797 shares during the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on DYN. HC Wainwright cut their price target on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, March 3rd. Wall Street Zen cut Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 2nd. Chardan Capital reaffirmed a “buy” rating and issued a $38.00 price target on shares of Dyne Therapeutics in a report on Monday, March 9th. JPMorgan Chase & Co. cut their price target on Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating for the company in a report on Tuesday, January 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $35.14.

View Our Latest Stock Report on DYN

Dyne Therapeutics Company Profile

(Get Free Report)

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

Read More

• Five stocks we like better than Dyne Therapeutics
• AI Dividend Increases: 3 Massive Winners Boosting Payouts
• Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader
• 5 Stocks Positioned to Benefit From the AI Inference Boom
• Meta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand Now

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.